G.
Thnx for posting....
Explanation of Thero's comments (what he means)
The IMPROVE-IT trial examined a drug called Ezetimibe which is a drug which blocks the absorption of cholesterol in the intestine..This has the effect of lowering cholesterol and is suggested as an add on to statins..or use in individuals who are statin intolerant. IMPROVE-IT ran for seven years (consider that zip), enrolled 18,000 souls (42% dropped out) generated about 5500 CVD events, cut the overall CVD events down from 34% to 32% (a "7% redux)...And now is being haled by many of the cardiolgist as the first successful statin add on. Over the seven year period of IMPROVE-IT the active arm only cut the event rates down 270 from the control
What has this got to do with Vascepa and the R=I? Simply put..Vascepa is also at this point, a statin add on..The IMPROVE-IT acceptance means Vascepa is facing a ridiculously low bar for success..Vascepa has a much lower number of side effects (Ezetimibe causes diarrhea)... What Thero is saying that even a high one digit percent improvement in the RRR would be a success in R-I considering that was the case in IMPROVE-IT...
Imagine when R-I comes in over 30%.....
":>) JL
Market Data 
Markets 
AI
